Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. - Wikidata - wikimedia - TriplyDB

Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

http://www.wikidata.org/entity/Q33382190

about

Advances in Diagnosis and Treatments for Immune Thrombocytopenia Contemporary management of primary immune thrombocytopenia in adults Human platelets and their capacity of binding viruses: meaning and challenges?Eltrombopag for the treatment of aplastic anemia: current perspectives Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival Treatment of immune thrombocytopenic purpura: focus on eltrombopag.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag.Biology and chemistry of thrombopoietic agents Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.Thrombopoietin receptor levels in tumor cell lines and primary tumors Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis Management of immune thrombocytopenic purpura in children: potential role of novel agents.Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia Eltrombopag in patients with chronic liver disease.Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.Thrombopoietin receptor agonists in primary immune thrombocytopenia.The biology of thrombopoietin and thrombopoietin receptor agonists.Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.The pharmacology and clinical application of thrombopoietin receptor agonists.Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.Thrombopoiesis-stimulating agents and myelodysplastic syndromes.Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro Adipose-Derived Mesenchymal Stem Cells (ADSCs) With the Potential to Ameliorate Platelet Recovery, Enhance Megakaryopoiesis, and Inhibit Apoptosis of Bone Marrow Cells in a Mouse Model of Radiation-Induced Thrombocytopenia.Eltrombopag for treatment of thrombocytopenia-associated disorders.The Eltrombopag antitumor effect on hepatocellular carcinoma.

P2860

Q26738630-3354077C-1D4E-41B7-87C8-0EF53E78D566 Q26853680-05266C67-903F-41D5-B1F0-30C23E4DD08B Q26997803-84E93A41-42FD-4A50-8FA4-3CC397FE0B41 Q28071710-8BA9AD19-1487-42D7-99E8-65359AFAF39F Q28546734-09C8C665-5C96-49C2-9F95-5505FCB7739A Q33385976-50687447-1754-454B-A359-55386F850318 Q33385999-B0F7DEB4-948D-4CD8-A1C1-2E760945F610 Q33387735-066DED77-D58F-43ED-9EE9-DE5C88EFE3E9 Q33387808-7B730C3B-2948-43E5-88E7-CFD2D9D7F969 Q33390625-FAF5D4A9-6AA9-41AE-A7C5-D0564982C163 Q33391009-37ED34C6-961F-423B-B32B-92BD5FC5B177 Q33394117-21011248-B27A-401A-8707-365189C29AAF Q33394544-C9E5C32D-36E2-4737-852B-1E28959472E0 Q33395863-5F286F18-8245-47EE-8415-C7F2729C0F06 Q33396286-3E2B8FB9-D7E2-45EF-B934-0290D8E53F49 Q33397968-6C504289-3FFB-4020-A541-45EC3764E087 Q33399437-675CA683-BC59-4724-89BD-76AEB2FDE49D Q33400092-4460D314-13C1-467D-B657-1C3B7CCAA118 Q33401421-749E6D46-9A7B-4491-B833-C13F77E1C60E Q33403234-8AE44A68-63D5-4254-9E62-2F964098844E Q33405057-5EF2E57F-960D-49D6-B00B-26091EE47D60 Q33405820-57E3BA82-FF48-4C94-8DB6-74E5D42AD569 Q33406127-6577577A-427B-49DB-8FBE-F36B8D97EC64 Q33406181-EC59CA47-82A8-4454-989C-643A6D9D8374 Q33407110-33DB3646-1749-494B-A3BE-3D7D7A7336BD Q33407623-CDB38A74-17D4-4FE2-94BD-583F1AA722E9 Q33408850-DBF45A64-DF7A-40D9-8A0F-5A4B451E5E6C Q33411387-B2347537-2B42-4824-AADC-52EC3D6024FC Q33412710-5A0BCE47-1512-4758-B0A0-A030B31CE81B Q33413160-2109212E-89BB-4E56-B283-B572D30EABE3 Q33413317-106F001C-CD60-4AC6-A7C7-6619246C39BB Q33414386-33477694-71E9-4599-9BD7-5B7E3CA7A443 Q33417608-0731D842-C588-4A00-84C4-4DE0471323C7 Q33417700-330CC6AD-F89F-48E5-9C51-D2B7B3558E75 Q33418303-41D456F8-3765-42ED-ACA2-9C273F37F587 Q33420207-A19AE9F6-0DB8-4577-81CC-79D84F433839 Q33420441-037C65AE-739B-4D82-BB6F-7902BD9D20A7 Q33422819-389F3869-12A0-4C28-86D4-CF034E05C58B Q33425805-1F5881DC-B100-4649-A49E-74C31B858178 Q33426135-8425AF87-102D-442F-AE50-419C913C7A16

P2860

Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

http://www.wikidata.org/entity/Q33382190

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Preclinical activity of eltrom ...... rombopoietin receptor agonist.

@ast

Preclinical activity of eltrom ...... rombopoietin receptor agonist.

@en

type

label

Preclinical activity of eltrom ...... rombopoietin receptor agonist.

@ast

Preclinical activity of eltrom ...... rombopoietin receptor agonist.

@en

prefLabel

Preclinical activity of eltrom ...... rombopoietin receptor agonist.

@ast

Preclinical activity of eltrom ...... rombopoietin receptor agonist.

@en

P1433

Q33382190-6724C305-8BEF-402B-9C3B-D3E6340A4EAF

P1476

Q33382190-EB911E05-6ECD-40D7-A8AC-C8EDE94049AD

P2093

Q33382190-01CC57A8-22F2-4B9F-AF9B-5CBBCB90FBFA

Q33382190-1E029BF6-68E0-4C81-B5FB-0674B52CD284

Q33382190-5E811BEF-2A14-41DA-983F-1B8C6BAA18BE

Q33382190-809B2D57-79E7-4FA9-BEB3-A07CBB8E4630

Q33382190-A843C8B6-74CD-4C43-AAD6-D015DF9E27A7

Q33382190-CF465664-68C8-4C41-B574-EC180BA147F8

Q33382190-DBD00919-09AF-4BC9-A790-DAB1E54D72C3

Q33382190-DC550C67-012A-4D32-B92E-555E02D6613C

Q33382190-E4EE477D-11FB-46DD-9D3F-E202A28F2D42

Q33382190-E5CDF169-977C-401D-A362-6BEE5AC5A278

P2860

Q33382190-00D3A242-2E04-435A-994B-BC993401A459

Q33382190-18A4268E-CE87-46B8-A9EB-91070DB32D3A

Q33382190-26F6EE49-0EDF-424B-B672-03FC1912B2FA

Q33382190-3788E7F9-AFA3-435B-801F-BC430AA086C3

Q33382190-3C569AF9-2B58-4CDF-B3C3-61AF66B2C729

Q33382190-4DF17E63-46A8-4D3E-BF78-0B344EC631FE

Q33382190-50F3EC85-4D3E-4479-91A3-BFE04FFD51EC

Q33382190-52F5D9E1-7F11-4CF1-9FBE-FE1BDA57692A

Q33382190-549E4B38-BDDB-49C2-8B10-133A61921580

Q33382190-5B000D94-7A41-49D6-BB9A-534E37783CA0

P304

Q33382190-FB4B0668-933B-4FC9-954B-34A54216C9BC

P31

Q33382190-5063818B-977F-42B4-8EF6-B26F96F5E070

P356

Q33382190-74E032A9-53F1-46FD-A191-B3A01B80F762

P433

Q33382190-DC2C7B40-5EF1-41BD-864B-304877F0CB7E

P478

Q33382190-406F9A01-99C7-4739-91D3-9D1E7A7DCED3

P50

Q33382190-D4B8C277-A2A6-4C73-BF85-00E41369CAAC

P577

Q33382190-092FCD28-5732-4BEE-9163-CAB616E602A1

P5875

Q33382190-E343ED29-170C-4CB0-BE12-9246015F8E2E

P698

Q33382190-B1566DC5-2801-421D-9DC5-A0A681878D0B

P932

Q33382190-42DFC110-6CAD-4A37-88FD-655231B27589

P356

STEMCELLS.2008-0366

P1433

P1476

Preclinical activity of eltrom ...... rombopoietin receptor agonist.

@en

P2093

Amy J Landis

http://www.w3.org/2001/XMLSchema#string

Christopher B Hopson

http://www.w3.org/2001/XMLSchema#string

Connie L Erickson-Miller

http://www.w3.org/2001/XMLSchema#string

Elizabeth I Valoret

http://www.w3.org/2001/XMLSchema#string

Evelyne Delorme

http://www.w3.org/2001/XMLSchema#string

Jon Rosen

http://www.w3.org/2001/XMLSchema#string

Juan I Luengo

http://www.w3.org/2001/XMLSchema#string

Julian M Jenkins

http://www.w3.org/2001/XMLSchema#string

Shin-Shay Tian

http://www.w3.org/2001/XMLSchema#string

Stephen G Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin

Thrombopoietin signal transduction requires functional JAK2, not TYK2

Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Diagnosis and management of aplastic anemia and myelodysplastic syndrome.

Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options.

Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy.

Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights.

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

P304

424-430

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/STEMCELLS.2008-0366

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23502560

http://www.w3.org/2001/XMLSchema#string

P698

19038790

http://www.w3.org/2001/XMLSchema#string

P932

2729672

http://www.w3.org/2001/XMLSchema#string